Temozolomide (Temodal®) – Malignant glioma (brain cancer)

Drug Name (Brand)	Temozolomide *(Temodal®)*
Indication	Malignant glioma (brain cancer)
Traffic Light Classification	Red
NICE TA (plus link)
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. NICE TA 23 April 2001: Patients with recurrent malignant glioma (brain cancer) who have failed first-line chemotherapy treatment with other agents (either because of lack of efficacy or because of side effects) may be considered for treatment with temozolomide. See fuller guidance. NICE TA No.121 June 2007: (Carmustine implants and) temozolomide for the treatment of newly diagnosed high-grade glioma. Temozolomide, within its licensed indications, is recommended as an option for treatment of newly diagnosed glioblastoma multiforme (GBM) in patients with a WHO performance status of 0 or 1. See full guidance for detail. April 2013: NHS England SCG took over commissioning responsibility for this treatment.
Date of TAG recommendation / ratification		7/1/2007	Review Date